Luye Pharma's Ruoxinlin approved for marketing in Macao

Luye Pharma Group (HKEX: 2186) announced that its Class 1 innovative antidepressant, Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), has been approved for marketing in Macao by the Pharmaceutical Administration Bureau of the Macao SAR Government. This marks an important milestone for Ruoxinlin®, which is China's first independently developed and patented chemical drug for the treatment of Major Depressive Disorder (MDD). The drug has demonstrated efficacy in clinical studies, significantly reducing anxiety, fatigue, and anhedonia, while improving cognitive abilities.